NBC 7 dives deep into the explosive popularity of the medications and explores both the life-changing benefits and the ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

Some fear weight-loss stocks are approaching bubble territory, but this incumbent player continues to prove its worth ...

Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

Health officials in England are considering a staggered roll out of an obesity drug due to high levels of demand. Nearly a quarter of a million people are expected to receive the Mounjaro jab over the ...

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...